Drugs / Adipose-Derived Mesenchymal Stem Cells
Adipose-Derived Mesenchymal Stem Cells
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04392206 | May 2020 → Dec 2026 expected | end stage renal failure | Houssam Farres, M.D. | Recruiting | No outcome recorded |
| Phase 1 | NCT02544802 | Jun 2015 → Jan 2019 | osteoarthritis, knee | Steminent Biotherapeutics Inc. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04055415 | Aug 2019 → Aug 2020 | pulmonary arterial hypertension | Liaocheng People's Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT03346967 | Nov 2017 → Feb 2020 | — | Vinmec Research Institute of Stem Cell and Gene Technology | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04855955 | — | Alzheimer disease | Celltex Therapeutics Corporation | No longer available | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT03869229 Comparator | Apr 2019 → Mar 2020 | osteoarthritis, hip, osteoarthritis, knee | Medical University of Warsaw | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2025-09-10 | Hope Biosciences Research Foundation | Regulatory Hope Bio’s stem cells zero in on Crohn’s Disease hope.bio ↗
The U.S. Food and Drug Administration (FDA) has authorized a Phase II clinical trial to evaluate whether the stem cells manufactured through Hope’s proprietary technology affect signs and symptoms of Crohn’s Disease in suffering people. |
| 2025-06-12 | Hope Biosciences Research Foundation | Regulatory Hope Bio hope.bio ↗
The U.S. Food and Drug Administration (FDA) has authorized an open label Phase Ib/IIa clinical trial to evaluate whether Hope Biosciences autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) reduce inflammation in the brain, improve brain activity, and/or slow progression of AD. |
| 2022-03-08 | Hope Biosciences Research Foundation | Results Hope Biosciences’ Cell Therapy Shown Safe, Beneficial for Rheumatoid Arthritis hope.bio ↗
Hope Biosciences’ adipose-derived mesenchymal stem cells are effective in improving joint function in patients actively suffering from Rheumatoid Arthritis (RA), finds a FDA-authorized Phase I/IIa pilot trial. |
| 2020-04-21 | Hope Biosciences Research Foundation | Regulatory Hope Biosciences Announces Third FDA-approved Clinical Trial for COVID-19 hope.bio ↗
Hope Biosciences announces FDA approval on their third clinical trial for COVID-19. |
| 2020-04-13 | Hope Biosciences Research Foundation | Regulatory Hope Biosciences Receives Second FDA Clearance for a Phase II Clinical Trial for COVID-19 hope.bio ↗ |
| 2020-04-06 | Hope Biosciences Research Foundation | Regulatory Stem Cell FDA approved trial hope.bio ↗
today announced that FDA has approved a Phase II clinical trial evaluating efficacy and safety of Hope Biosciences’ autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) to provide immune support against COVID-19. |
| 2019-11-20 | Hope Biosciences Research Foundation | Regulatory Hope Biosciences Receives FDA Approval to Commence Groundbreaking Clinical Trial for Alzheimer hope.bio ↗ |
All press releases naming this drug 7 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-09-10 | Hope Biosciences Research Foundation | Hope Bio’s stem cells zero in on Crohn’s Disease hope.bio ↗ |
| 2025-06-12 | Hope Biosciences Research Foundation | Hope Bio hope.bio ↗ |
| 2022-03-08 | Hope Biosciences Research Foundation | Hope Biosciences’ Cell Therapy Shown Safe, Beneficial for Rheumatoid Arthritis hope.bio ↗ |
| 2020-04-21 | Hope Biosciences Research Foundation | Hope Biosciences Announces Third FDA-approved Clinical Trial for COVID-19 hope.bio ↗ |
| 2020-04-13 | Hope Biosciences Research Foundation | Hope Biosciences Receives Second FDA Clearance for a Phase II Clinical Trial for COVID-19 hope.bio ↗ |
| 2020-04-06 | Hope Biosciences Research Foundation | Stem Cell FDA approved trial hope.bio ↗ |
| 2019-11-20 | Hope Biosciences Research Foundation | Hope Biosciences Receives FDA Approval to Commence Groundbreaking Clinical Trial for Alzheimer hope.bio ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adipose Derived Mesenchymal Stem Cells | “Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)” NCT03869229 ↗ |
| Known as | ADMSC | “Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)” NCT03869229 ↗ |
| Known as | ADMSCs | “Evaluation of Autologous Adipose Derived Mesenchymal Stem Cells (AD-MSCs) Therapy on Sexual Hormone Deficiency in the Middle-aged Patients: an Open-label, Single-group Clinical Trial” NCT03346967 ↗1“autologous adipose-derived mesenchymal stem cells (ADMSCs) treatment” NCT02544802 ↗ |
| Known as | ADSC | “Adipose tissue-derived mesenchymal stem/stromal cells (ADSC) were isolated by type I collagenase digestion and cultured at the Stem Cell Core Facility under ISO 14644-1.” PMID 34129158 ↗ Jun 2021 |
| Known as | AMSC | “Adipose Derived Mesenchymal Stem Cells (AMSC) use” NCT04392206 ↗ |
| Modality | Cell therapy | “autologous adipose-derived mesenchymal stem cells (ADMSCs)” NCT02544802 ↗ |
| Route | Other | “Three intra-articular injections of autologous ADMSCs” NCT02544802 ↗ |